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Osteopontin: a bridge between bone 
and the immune system
Ellen M. Gravallese
Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Boston,
Massachusetts, USA
The molecular mechanisms underlying the putative role of osteopontin
in the chronic inflammatory disease rheumatoid arthritis are unclear. A
study in a murine model of arthritis now demonstrates that a specific
antibody directed against the exposed osteopontin epitope SLAYGLR
(see the related article beginning on page 181) is capable of preventing
inflammatory cell infiltration in arthritic joints.
J. Clin. Invest. 112:147–149 (2003). doi:10.1172/JCI200319190.
In recent years a number of studies
have linked factors involved in in-
flammation to those critical for
bone physiology and remodeling.
One well described story is that of
the receptor-activator of NF-κB lig-
and (RANKL)/osteoprotegerin (OPG)
system, which plays a role in the
interaction between dendritic cells
and T cells in the immune system
and is the critical regulatory system
for bone remodeling under physio-
logic conditions (1, 2). The RANKL/
OPG system is also likely to play an
important role in several forms of
pathologic bone loss, including that
seen in osteoporosis, certain forms of
cancer, and inflammatory arthritis
(3). There is mounting evidence for
the role of another cytokine, osteo-
pontin (OPN; “bone-bridging” pro-
tein), also known as early T cell acti-
vation gene-1 (Eta-1), in providing a
link between the immune system and
bone. In this issue of the JCI,
Yamamoto et al. (4) provide impor-
tant new evidence indicating a role
for OPN in the pathogenesis of
inflammatory arthritis and associat-
ed joint destruction.
The role of OPN in bone 
and in the immune system
OPN is a phosphorylated glycoprotein
secreted by activated macrophages,
leukocytes, and activated T lympho-
cytes, and present in extracellular flu-
ids, at sites of inflammation, and in the
ECM of mineralized tissues (5, 6). This
cytokine mediates important cell-
matrix and cell-cell interactions. OPN is
abundant in bone, where it facilitates
the attachment of osteoclasts to the
bone matrix via an interaction with cell
surface αvβ3 integrin and CD44, the
hyaluronic acid receptor (7). OPN–/–
mice have a subtle bone phenotype,
with delayed and impaired bone resorp-
tion (7). In the immune system, OPN
plays a role in chemotaxis, leading to
the migration of macrophages and den-
dritic cells to sites of inflammation.
Activation of T lymphocytes results in
an increase in OPN transcription, hence
its alternative designation as Eta-1.
Weber et al. have demonstrated that
OPN is a T lymphocyte suppressor fac-
tor and that it enhances B lymphocyte
Ig production and proliferation (8). In
addition, OPN is an important cyto-
kine mediating Th1 immunity (9).
OPN interacts with a variety of cell
surface receptors, including the αvβ3,
αvβ5, αvβ1, α4β1, α8β1, and α9β1 inte-
grins, as well as CD44. Binding of OPN
to these cell surface receptors stimulates
cell adhesion, migration, and specific
signaling functions. The major integrin-
binding site in OPN is the arginine-
glycine-aspartate (RGD) integrin-bind-
ing motif, which is required for the
Address correspondence to: Ellen M.
Gravallese, Beth Israel Deaconess Medical
Center, Harvard Institutes of Medicine, 
Room 241, 4 Blackfan Circle, Boston,
Massachusetts 02115, USA. 
Phone: (617) 667-0717; Fax: (617) 975-5299;
E-mail: egravall@bidmc.harvard.edu.
Conflict of interest: The author has declared
that no conflict of interest exists.
Nonstandard abbreviations used: receptor-
activator of NF-κB ligand (RANKL);
osteoprotegerin (OPG); osteopontin (OPN);
early T cell activation gene-1 (Eta-1);
rheumatoid arthritis (RA); collagen-induced
arthritis (CIA); collagen antibody–induced
arthritis (CAIA).
148 The Journal of Clinical Investigation | July 2003 | Volume 112 | Number 2
adherence of many cell types to OPN.
However, other sequences within OPN
have also been shown to mediate cell
adherence. For example, cleavage of
human OPN by thrombin exposes the
SVVYGLR sequence (SLAYGLR in the
mouse), promoting the adherence of
cells expressing α9 and α4 integrins.
Potential role for OPN 
in the pathogenesis 
of inflammatory arthritis
Several prior studies have suggested an
important role for OPN in the patho-
genesis of inflammatory arthritis. OPN
mRNA and protein have been demon-
strated to be expressed in synovial tis-
sues from patients with rheumatoid
arthritis (RA), predominantly by fibro-
blastic cells, and at sites of pannus inva-
sion into cartilage (10). In murine col-
lagen-induced arthritis (CIA), OPN was
detected in synovial tissues and at sites
of osteoclast-mediated bone resorption,
where its expression colocalized to sites
of αvβ3 integrin expression (11). OPN
has thus been implicated in the process
of joint destruction in arthritis.
In their report in this issue of JCI,
Yamamoto et al. (4) studied CIA and an
animal model of RA known as collagen
antibody–induced arthritis (CAIA).
Arthritis was induced by the transfer of
anti–type II collagen antibodies in
C57BL/6 mice boosted with an intra-
peritoneal injection of LPS. These au-
thors report that splenic monocytes
from arthritic mice expressing α4 and
α9 integrins demonstrated enhanced
migration toward thrombin-cleaved
OPN compared with splenic monocytes
from nonarthritic mice. Of note is the
fact that the ratio of the thrombin-
cleaved form of OPN to noncleaved
OPN was previously shown to be signif-
icantly increased in the plasma and syn-
ovial fluid of patients with RA compared
with plasma from healthy controls and
from patients with osteoarthritis (11).
Furthermore, treatment of mice with an
antibody (M5 Ab) directed against the
sequence SLAYGLR, exposed by throm-
bin cleavage of murine OPN, inhibited
synovitis and inflammatory cell infiltra-
tion into the joints of treated mice com-
pared with those of arthritic control
mice (4). M5 Ab treatment also resulted
in protection from cartilage destruction
in this murine model of RA.
In vitro studies were performed to
demonstrate that the M5 Ab blocked
the formation of osteoclast-like cells
induced from bone marrow–derived
precursors by treatment with RANKL
and M-CSF. In addition, this antibody
blocked the induction of calcium release
from bone by parathyroid hormone
(PTH) and IL-1α in vitro (4). It has been
previously demonstrated that PTH-
induced bone resorption is dependent
on OPN (12). These results suggest that
one role of the M5 Ab in joint protec-
tion could be the blockade of osteoclast
differentiation and function in vivo. A
limitation of this study is that bone
destruction was not directly assessed in
the in vivo animal studies presented,
and tartrate-resistant acid phosphatase–
positive osteoclast-like cells were not
quantitated in mice with and without
M5 Ab treatment. In addition, since M5
Ab treatment inhibits joint inflamma-
tion in this animal model, protection
from joint destruction may be a second-
ary phenomenon related to the general
decrease in inflammation. Therefore a
direct role of OPN in bone erosion in
this model could not be determined.
Given the important role of OPN in
bone remodeling, such studies would be
of great interest. Nonetheless, the effects
on the clinical and histologic parame-
ters studied provide convincing addi-
tional evidence for a role of OPN in
arthritic inflammation, and specifically
for its role in the recruitment of inflam-
matory cells to arthritic joints.
Arthritis in the setting 
of OPN deficiency
Based on this information, one might
expect that arthritis would be signifi-
cantly attenuated in mice deficient in
OPN. In fact this has been demonstrat-
ed in a CAIA model of RA (13) similar
to that used in the study presented in
this issue of JCI (4). OPN-deficient mice
were found to have marked attenuation
of joint swelling and articular cartilage
destruction compared with arthritic
wild-type mice and had no increase in
urinary levels of deoxypyridinoline, a
marker of bone destruction (13). These
data support a role for OPN in both the
inflammatory and the joint-destructive
processes in arthritis. Interestingly,
however, these results were called into
question in a recent report in Science
(14) in which OPN was deleted by
homologous recombination of strain
129–derived cells, and backcrossed into
a CIA- and CAIA-susceptible strain for
12 generations. These authors then in-
duced CIA and CAIA in the OPN-defi-
cient mice and in littermates and de-
monstrated no effect of OPN deficiency
in either form of murine arthritis. They
concluded that prior observations in
OPN-deficient mice showing protec-
tion from arthritis may have resulted
from the deletion of polymorphic genes
linked to OPN from strain 129, rather
than from the deletion of OPN itself.
These authors provided a list of several
other genes within the deleted locus
that could be important for arthritis
pathogenesis.
The study of Yamamoto et al. (4)
certainly adds to our understanding
of the mechanisms by which OPN
contributes to the pathogenesis of
inflammatory arthritis. Given the
clear and important role of OPN in
inflammatory processes and bone
remodeling, it will be of considerable
interest to resolve some of the remain-
ing controversies regarding the role of
OPN in this disease.
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Salicylic acid: an old dog, new tricks, 
and staphylococcal disease
Mathias Herrmann
Department of Bacteriology and Hygiene, Institute of Medical Microbiology and Hygiene,
University of Saarland, Homburg/Saar, Germany
Aspirin has been shown to cause a reduction in the virulence of Staphylo-
coccus aureus–associated endocarditis. A new study (see the related article
beginning on page 222) reveals that salicylic acid, the major metabolite of
aspirin, acts at the level of transcription to downregulate the production of
fibrinogen, fibronectin, and α-hemolysin — virulence factors necessary for
bacterial replication in host tissues and, now, potential therapeutic targets.
J. Clin. Invest. 112:149–151 (2003). doi:10.1172/JCI200319143.
One hundred and twenty years after its
initial description as the pathogen that
causes sepsis and abscesses (1), Staphylo-
coccus aureus remains a dangerous organ-
ism. Staphylococcal endocarditis is on
the rise (2) and still causes significant
mortality (3). The methicillin-resistant
S. aureus (MRSA) epidemic has entered a
new era due to the spread of MRSA into
the community (4) and acquisition of
new resistance cassettes with the poten-
tial for genetic transfer (5). The advent
of fully vancomycin-resistant, methi-
cillin-resistant clinical isolates (6) has
further weakened the available arma-
mentarium against this pathogen.
Importance of staphylococcal
attachment and invasion in
endovascular disease
S. aureus is a nonmotile microorganism
with a particular propensity to colonize
biologic or artificial substrates using a
battery of pathogenicity factors (7),
allowing for specific bacterial attach-
ment. This can be followed by cellular
invasion and subsequent tissue degra-
dation. Several lines of evidence clearly
indicate that the interaction with host
proteins and platelets is instrumental in
the development of disease. A plethora
of bacterial factors — either wall bound
(8) or secreted (9, 10) — mediate binding
of and attachment to ECM molecules
such as fibronectin, fibrinogen, colla-
gen, and vWF. Work with deletion
mutants and complemented heterolo-
gous hosts has demonstrated the par-
ticular role of adhesins that recognize
fibronectin (such as fibronectin-binding
protein A) and fibrinogen (such as
clumping factor A, ClfA), allowing for
cellular invasion and production of
experimental endocarditis (11, 12), and
gfp reporter assays from endocarditis
models clearly indicate that activation
of global regulators that coordinate
adhesin and toxin expression, such as
agr and sar, occurs in vivo (13, 14).
Distinctive effects of acetylsalicylic
acid and salicylic acid on platelets 
and bacteria
A particular role of platelets in the
pathogenesis of staphylococcal endo-
carditis has been suggested since the
early observation by Durack of bacterial
interaction with fibrin-platelet matrices
at sites of nonbacterial thrombotic
endocarditis (15) and the series of
reports by Clawson et al. on the interac-
tion of S. aureus with purified platelets
(16). In the early 1990s, experiments
with surface-activated platelets suggest-
ed to our group the importance of fib-
rinogen and S. aureus clumping factor in
the bacteria-platelet interaction (17).
These observations were subsequently
confirmed and extended by use of a low-
platelet-binding mutant expressing a
mutated ClfA protein (18) that displays
diminished virulence in an endocarditis
model (19), and by identification of the
secreted fibrinogen-binding proteins
Coa and Efb in phage-display panning
assays (20) (Figure 1).
While these observations pointed
toward complex but, according to their
adhesive function, rather propatho-
genic events at the bacteria-endocardi-
um interface, the role of platelets had
to be reevaluated after the discovery
that they function as specialized
inflammatory cells (21) in response to
secretion of antimicrobial peptides. In
fact, paradoxically, hyperexpression of
α-toxin by S. aureus results in dimin-
ished virulence in experimental endo-
carditis, possibly because of the release
of platelet microbicidal proteins (22).
The attributed role of platelets in the
disease process that results in endovas-
cular infection has prompted a number
of researchers to interfere with platelet
function for prevention or treatment of
endocarditis. Acetylsalicylic acid (ASA,
aspirin) has been used in vitro and in a
number of experimental models to
reduce vegetation sizes and to mitigate
the course of disease (23–25). Similar
effects have also been observed by
Kupferwasser et al. (26). However, when
they studied its metabolite, salicylic acid
(SAL), in parallel to ASA, they made the
interesting observation that pretreat-
ment of bacteria with SAL reduced
attachment to the valvular epithelium
to an even greater extent than adminis-
tration of ASA. This observation was
accompanied by the in vitro finding that
SAL-pretreated S. aureus cells bound to
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